Objective To evaluate the effects of a novel inducible nitric oxide synthase (iNOS) inhibitor (FR260330) in prevention of chronic rejection in a model of rat aortic allograft and to investigate the mechanism of the arterial wall lesion of chronically rejecting solid organ grafts. Methods Male Lewis (LEW, RT1~ l) rats received male ACI (RT1~ a) aorta allografts or LEW aorta isografts. Seven groups (n≥12) were involved in this study. FR260330 and/or tacrolimus were administered orally for 14 or 90 days according to protocol. The degree of intimal proliferation of graft aorta was determined by a computerized image system.Results Both low and high doses of FR260330 or tacrolimus treated grafts showed significantly decreased intima/(intima+media) ratios at day 90 compared with placebo controls. Combined therapy of low-dose of FR260330 with low-dose of tacrolimus produced a significant decrease of intima/(intima+media) ratios with intact endothelium as compared with placebo controls. Anti-?-actin immunohistochemical staining demonstrated that one of the mechanisms of intimal proliferation was related to migration of vascular smooth muscle cells. The intima in iNOS inhibition groups was more smooth than in placebo control group and low-dose FK506 treated groups.Conclusions A selective inhibitor of nitric oxide synthase, FR260330 plays a protective role in chronic aortic allograft rejection in the rat. Combined therapy of low-dose of FR260330 with tacrolimus produces significant protection of immune injury and may serve to improve long-term graft survival and function.

Adolescent ; Adult ; Aged ; Agranulocytosis ; chemically induced ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Cisplatin ; administration & dosage ; adverse effects ; Cyclophosphamide ; administration & dosage ; adverse effects ; Doxorubicin ; administration & dosage ; adverse effects ; Etoposide ; administration & dosage ; adverse effects ; Female ; Follow-Up Studies ; Humans ; Lymphoma, T-Cell, Peripheral ; drug therapy ; Male ; Middle Aged ; Nausea ; chemically induced ; Prednisone ; administration & dosage ; adverse effects ; Remission Induction ; Vincristine ; administration & dosage ; adverse effects ; Young Adult

Cell Line, Tumor ; Humans ; Leukemia-Lymphoma, Adult T-Cell ; metabolism ; NF-kappa B ; metabolism ; Proto-Oncogene Proteins ; metabolism ; Transcription Factors ; metabolism

Objective To investigate the effect of 1,25-(OH)2D3 and salvia miltiorrhiza on T cell subsets and cytokines in rats after allogeneic bone marrow transplantation.Methods Female Wistar rats were used as recipients and male SD rats were used as donors.All Wistar rats were divided into aGVHD group and intervention groups at random,and the intervention groups were further divided into 1,25-(OH)2D3 group,salvia miltiorrhiza group and combination group.The changes of T cell subsets (CD4+ and CD8+) and cytokine (IL-2,IFN-?,IL-4 and IL-10) in every group were detected and measured.Results When the presentation of aGVHD was relatively conspicuous,CD4+ and CD8+ were increased,and the increase of CD4+ was predominant.Compared with the difference prior to transplantation,the difference was statistically significant (P

Based on the strain breeding theory and metabolic engineering theory, A high-yield mutant of Lactobacillus Thermophilus ATCC8317 was obtained through the compound inducements by the original Acetic acid-Sodium acetate plate and the productivity increased 210%.The best media components included saccharifying corn,malt powder 30g/L,peptone 5g/L.Based on the variety of specific cell growth rate and specific L-lactic acid production rate at different temperatures, the strategy of temperature control was obtained. The total product of L-lactic acid reached 135g/L besides the rate of glucose consumed and the average L-lactic acid productivity were up to 95% and 2.25g/(L?h) respectively.

This paper developed a calculation method to acquire the yield load P of bone plate during four-point bending test. This method is based on the displacement--force (δ-F) curve function f(M)(δ) obtained from the test, each slope of the curve was calculated using piecewise smooth function and the line segment in f(M)(δ) elastic deformation area was searched by setting the minimum slope T. Slope S was obtained through linear fit so as to build parallel displacement function f(L)(δ). Then, approximating intersection point of f(M)(δ) and f(L)(δ) was obtained through linear interpolation. Thus, yield load P was acquired. The method in the paper was loyal to YY/T 0342-2002 regulation and was liable to program calculation. The calculating process was nothing to do with whether the initial point during the test was preloaded or unloaded, and there was no need to correct the original point. In addition, T was set in an ideal fitting level guaranteed by the fitting coefficient of determination R2, and thus S was very close to the real value, and P was with a high accuracy.
Biomechanical Phenomena ; Bone Plates ; Humans ; Models, Theoretical ; Posture ; Weight-Bearing

Adult ; Dust ; Humans ; Middle Aged ; Noise, Occupational ; Occupational Diseases ; epidemiology ; Risk Factors ; Welding ; Workplace ; Young Adult

Objective To investigate the factors impact on the mortality of severe acute pancreati- tis(SAP)and the related treatment methods.Methods The data from 24 patients died of SAP from Jan- uary 1993 to June 2006 were retrospectively analyzed.The factor that impact motality and treatment measures were also analyzed.Results The mortality of patients with SAP was 6.65%(24/361).Multi- ple organ dysfunction sydrome(MODS)was the main cause of death in early stage of SAP.The infection was an important cause in later stage.The mortality was higher in SAP patients with other complications than those without.Conclusions MODS is the main cause of death in early stage.Close monitoring and supportive treatments in early stage can reduce mortality.Individualized treatments,including nonsurgi- cal,surgical and interventional therapy should be adopted in later stage,with emphases on reducing com- plications.

Objective To investigate the effectiveness of malononitrilamide 715 (FK778) in combination with tacrolimus in prevention of acute renal allograft rejection in Vervet monkeys. Methods Eleven groups ( n ≥4/group) were involved in this study. FK778 and tacrolimus were administered orally for 60 days according to protocol. Proliferation assay was used to evaluate the effect of FK778 plus tacrolimus on monkey lymphocytes, after activation with T or B cell specific mitogens. Results Naive controls rejected renal graft with a median survival time (MST) of 8.0 days in group 1. When recipient monkeys were treated with tacrolimus 1.0 mg?kg -1 ?d -1 in group 2 or FK778 2.5 mg?kg -1 ?d -1 in group 3, the MST was 16.0 days ( P = 0.001 ) and 11.0 days ( P = 0.266 ), respectively. Combination therapy of these two agents at the same doses immediately after transplantation resulted in a MST of 25.0 days ( P = 0.016 ) in group 4. When tacrolimus was initiated immediately after transplantation and FK778 treatment was delayed until day 7 after surgery in group 5, recipient survivals were significantly prolonged to 38.0 days ( P = 0.02 ). These results were repeatable when FK778 5.0 mg?kg -1 ?d -1 ( 9.0 days, P = 0.544 in group 6) was combined with tacrolimus 1.0 mg?kg -1 ?d -1 immediately after transplantation ( 8.0 days, P = 0.339 ) in group 7, or when FK778 was delayed 7 days ( 60.0 days, P = 0.002 ) in group 8. Furthermore, it was also repeatable when FK778 10 mg?kg -1 ?d -1 was combined with tacrolimus 1.0 mg?kg -1 ?d -1 with a 7 day delay. Proliferation assay in the combination groups revealed that 88.8 % (8/9) produced additive to synergistic effects in B cells, while 66.6 % (6/9) produced moderate antagonistic effects in T cells. Conclusion A significant prolongation of renal allograft survival was produced when FK778 administration was delayed by 7 days combined with tacrolimus in Vervet monkeys. And the combination of FK778 with tacrolimus in vitro produces synergistic inhibition on B cells proliferation, but not on T cells.

Adult ; Anti-Inflammatory Agents ; therapeutic use ; Churg-Strauss Syndrome ; drug therapy ; pathology ; Follow-Up Studies ; Humans ; Male ; Methylprednisolone ; therapeutic use